Trial · NCT02920476
TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)
NCT02920476, Phase 2, Completed, University of Florida; results first posted 2019-12-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003). Trials, record NCT02920476. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02920476
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)
- NCT number
- NCT02920476
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 4 participants, actual
- Lead sponsor
- University of Florida
- Conditions
- Squamous Cell Lung Carcinoma
- Interventions
- TAS-102
- First posted
- 2016-09-30
- Last updated
- 2022-06-23
- Results first posted
- 2019-12-17
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) | 1 year | To determine the percentage of subjects who achieve an objective response by RECIST 1.1 criteria. ORR is defined as the number of participants who achieved either a partial or complete response by RECIST 1.1 criteria. By these criteria, Complete Response (CR) is defined as the disappearance of all target lesions and Partial Response (PR) is defined as a decrease of at least 30% in the sum of the longest diameter of the target lesions. Subjects must have received at least 2 cycles of therapy to be evaluable for this outcome measure. |
| Secondary | Clinical Benefit Rate | 1 year | To determine the percentage of subjects who derive clinical benefit by RECIST 1.1 criteria. The clinical benefit rate is defined as the percentage of subjects who achieved either a complete or partial response or stable disease by RECIST 1.1 criteria. RECIST 1.1 criteria defines a partial response as a decrease of the sum of the largest diameter each target lesion by at least 30%. A complete response is defined as the disappearance of all target lesions (except lymph nodes, whose short axis must measure 10 mm or less). By RECIST 1.1 criteria, a subject is considered to have stable disease when the sum of the largest diameter of the target lesions has neither decreased enough to qualify as a partial response not increased enough to qualify as progressive disease. |
| Secondary | Overall Survival (OS) | 1095 days | To determine the overall survival in days |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Objective Response Rate (ORR) | 1 year | Only 2 of the 4 subjects accrued to the study were evaluable for treatment response. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Clinical Benefit Rate | 1 year | Only 2 of the 4 participants accrued were evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Overall Survival (OS) | 1095 days | days | MEAN |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) | Treatment Arm | 0 | Participants | ||
| Clinical Benefit Rate | Treatment Arm | 0 | Participants | ||
| Overall Survival (OS) | Treatment Arm | 449.25 | Full Range 165 to 1095 | days |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment Arm | 4 | |
| Overall Study | COMPLETED | Treatment Arm | 3 | |
| Overall Study | NOT COMPLETED | Treatment Arm | 1 |
Source ClinicalTrials.gov
Adverse events21
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Non-cardiac chest pain | General disorders | Treatment Arm | 1 | 4 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Treatment Arm | 1 | 4 | |
| other | Anorexia | Metabolism and nutrition disorders | Treatment Arm | 1 | 4 | |
| other | Bloating | Gastrointestinal disorders | Treatment Arm | 1 | 4 | |
| other | Constipation | Gastrointestinal disorders | Treatment Arm | 3 | 4 | |
| other | Dysgeusia | Nervous system disorders | Treatment Arm | 1 | 4 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Treatment Arm | 2 | 4 | |
| other | Fatigue | General disorders | Treatment Arm | 2 | 4 | |
| other | Fever | General disorders | Treatment Arm | 1 | 4 | |
| other | Hot flashes | Vascular disorders | Treatment Arm | 1 | 4 |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment Arm | 4 | 4 |
| Total, other adverse events | Treatment Arm | 4 | 4 |
| Total, serious adverse events | Treatment Arm | 3 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02920476
GET https://conductscience.org/api/trials/v1/NCT02920476/events?page=2